Consultant Renal Physician/Honorary Clinical Associate Professor,
Director of Undergraduate Medical Education
Leeds Teaching Hospitals Trust

Andrew studied renal medicine in Leicester and at Washington University USA, where he investigated the molecular mechanisms underlying acute kidney injury.

Andrew provides a specialist renal opinion for critically ill patients on the intensive care units across Leeds. He was an expert adviser on the National Clinical Enquiry into Patient Outcomes and Death (NCEPOD) ‘Adding Insult to Injury’, acute kidney injury report in 2009. He was appointed to the Department of Health Acute Kidney Injury Delivery Board to address the recommendations proposed in the NCEPOD report.

In 2011 Andrew was appointed Chair of the NICE accredited Renal Association Clinical Practice Guidelines Committee. He was a member of the NICE AKI and IV Fluid Therapy Clinical Practice Guideline Committee and is currently on the NICE AKI and RRT Quality Standards Group. Andrew is Co-Chair of the UK Kidney Research Consortium AKI Study Group and his research is focused on biomarker discovery and development. He is a member of the ISN AKI committee and Co-Chair of the Education workstream of the ISN ‘0 by 25’ initiative. Andrew is Chief Investigator for the NIHR Kidney transplant biomarker study and Epidemiology of AKI in Critically Ill Patients on ICU. He is a co-applicant on a £1.2M grant from the NIHR for the Diagnostic Evaluation Cooperative to investigate the clinical and cost effectiveness of biomarkers in the NHS. Most recently he has secured NIHR funding to evaluate ways of preventing acute kidney injury in the community and HTA funding to analyse the economic impact of acute kidney injury on the ICU.

Chair of the NHS England AKI Risk workstream